PEACCEL at glance

What makes PEACCEL different is that it can produce massive amounts of synthetic data to train its ML/DL platform. Other companies have taken the shortcut of relying on existing datasets which are often messy and of low quality.
The innov’SAR core approach is interpolative, extrapolative and predicts out-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 Billion mutants per day.
PEACCEL is definitely the only company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of “hit rate”.

PEACCEL is managed by a seasoned multinational team accumulating scientific, business and management experienced in chemical, pharmaceutical and biotech industry.
The company operates in Paris (France) and Cambridge (MA, USA).